tiprankstipranks

CANC ETF Price & Analysis

Compare

CANC ETF Chart & Stats

ETF Overview

Tema Oncology ETF

The Tema Oncology ETF (Ticker: CANC) is a specialized investment vehicle designed for those seeking exposure to the dynamic and rapidly evolving health care sector. With a concentrated focus on the Pharma, Biotech & Life Sciences niche, this ETF offers investors a gateway into the world of oncology, where groundbreaking advancements and innovative treatments are continuously reshaping the landscape of cancer care. Harnessing the expertise of industry leaders and pioneers in cancer research and treatment, the Tema Oncology ETF strategically curates a portfolio of companies at the forefront of developing transformative therapies and cutting-edge technologies. By investing in this ETF, investors gain access to a diversified range of firms engaged in the discovery, development, and commercialization of oncology drugs and solutions. The fund aims to capture the growth potential inherent in the oncology field, driven by increasing global demand for effective cancer treatments and the relentless pursuit of medical breakthroughs. As the fight against cancer intensifies, the Tema Oncology ETF positions itself as a compelling choice for investors looking to align their portfolios with the promising prospects of the health care sector's most critical and high-impact areas.

Tema Oncology ETF (CANC) Fund Flow Chart

Tema Oncology ETF (CANC) 1 year Net Flows: $48M

CANC ETF FAQ

What was CANC’s price range in the past 12 months?
CANC lowest ETF price was $23.97 and its highest was $30.11 in the past 12 months.
    What is the AUM of CANC?
    As of Feb 20, 2025 The AUM of CANC is 67.35M.
      Is CANC overvalued?
      According to Wall Street analysts CANC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does CANC pay dividends?
        CANC pays a Annually dividend of $0.728 which represents an annual dividend yield of 2.85%. See more information on CANC dividends here
          How many shares outstanding does CANC have?
          CANC has 2,640,000 shares outstanding.
            Which hedge fund is a major shareholder of CANC?
            Currently, no hedge funds are holding shares in CANC

            CANC ETF Smart Score

            For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.​

            Top 10 Holdings

            Name
            Weight %
            AstraZeneca plc
            5.76%
            Eli Lilly And Company
            5.37%
            Bridgebio Pharma
            4.85%
            Revolution Medicines, Inc.
            4.10%
            Merck & Company
            3.97%
            Genmab (Otc)
            3.89%
            Roche Holding AG
            3.89%
            Bristol-Myers Squibb Company
            3.71%
            Beigene, Ltd.
            3.68%
            Exelixis
            3.64%
            Total42.84%
            See All Holdings
            Popular ETFs
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis